In 2024, the business plans to partner with Novartis’ Sandoz to co-produce and market Humira biosimilar Hyrimoz (adalimumab-adaz) for more than 80 percent less than the biologic’s price, which is nearly $7,000 a month.
“The Cordavis products will be FDA approved, high quality and easy for patients to use and will help ensure consistent long-term supply of affordable biosimilars,” CVS said in a statement.
The Cordavis launch coincides with a workforce restructuring of about 2 percent of its total workforce. CVS is cutting 5,000 jobs and has filed WARN notices for laying off 2,705 workers across nine states.
